Pharmaceuticals
Antengene Announces First Patient Dosed in the Nivolumab Combination Portion of the Clinical Study Evaluating the ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors in the United States
- ATG-017 is an oral, potent and selective small molecule ERK1/2 inhibitor. Antengene has exclusive global rights to develop, commercialize, and manufacture ATG-017 - The combination portion of the ERASER study, the first-in-human (FIH) study of ATG-017, was designed to evaluate the safety/tole...
2023-07-18 08:30
3102
ALZHEIMER'S ASSOCIATION STATEMENT ON DONANEMAB PHASE 3 DATA REPORTED AT AAIC 2023
AMSTERDAM, July 17, 2023 /PRNewswire/ -- The data reported today by Eli Lilly from theTRAILBLAZER-ALZ 2 clinical trial of donanemab in early symptomatic Alzheimer's disease demonstrate an important advancement in Alzheimer's research and treatment. The full Phase 3 data was reported at the Alzh...
2023-07-17 21:15
3782
Antengene Announces XPOVIO® Regulatory Approval in Hong Kong for the Treatment of Relapsed and/or Refractory Multiple Myeloma
* XPOVIO® (selinexor) is the first and only XPO1 inhibitor approved in Hong Kong * XPOVIO® has received regulatory approvals in 41 countries and regions includingthe United States, Israel, the United Kingdom, the European Union (the 27 member countries includingFrance and Italy), Canada, Norw...
2023-07-17 08:30
3675
Red Marrow Peptide-A Major Breakthrough in Human Health Engineering
BEIJING, July 14, 2023 /PRNewswire/ -- 1.8 g! This figure refers to the weight of red marrow which can be extracted from a 100 kg young yak growing in no-human zone ofQinghai and enjoys the reputation of "the key of cardiovascular health". It is called the most perfect "blood scavenger", ...
2023-07-14 12:51
3099
Menarini Silicon Biosystems announces the launch of its new CELLSEARCH® CTC test with the DLL3 biomarker for small cell lung cancer
This new CELLSEARCH Circulating Tumor Cell (CTC) test is now available as a Research Use Only (RUO) lab service inNorth America and Europe. It is currently intended for basic and pharmaceutical research and it is the latest example of how Menarini Silicon Biosystems continues its development of c...
2023-07-13 20:00
4244
Sirnaomics to Present Latest Developments on Two Proprietary Delivery Platforms at Upcoming Industry Conferences
HONG KONG, Germantown, Md. and SUZHOU, China, July 12, 2023 /PRNewswire/ -- Sirnaomics Ltd.(the "Company", stock code: 2257, together with its subsidiaries, the"Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, hereby...
2023-07-12 20:45
3992
Raya Therapeutic announces early-stage R&D collaboration with argenx
MONTREAL, July 12, 2023 /PRNewswire/ -- Raya Therapeutic Inc., ("Raya") a mission-driven company focused on the treatment of neurodegenerative diseases, has entered into an early-stage R&D collaboration with argenx. The collaboration focuses on testing combinations of Raya's pipeline of targeted ...
2023-07-12 19:07
2750
Biosyngen's First-in-class Cell Therapy BRG01 Receives FDA Fast Track Designation
SINGAPORE, July 12, 2023 /PRNewswire/ -- On July 6, 2023, Biosyngen received an official notification from the U.S. Food and Drug Administration (FDA) granting Fast Track Designation (FTD) to its revolutionary first-in-class immunotherapy, BRG01, for the treatment of relapsed/metastatic nasophary...
2023-07-12 13:38
4515
Creating the China-Singapore Translational Medicine Center - Biosyngen's pursuit to be a leading player in the CGT industry globally hits new milestone.
SINGAPORE, July 12, 2023 /PRNewswire/ -- This is a model of cooperation between Singapore and China, more importantly, working jointly in the area of research and development. Through this initiative, China Singapore Knowledge City paths the way to attract both local and overseas therapeutic asse...
2023-07-12 10:32
3927
Sciwind Biosciences Announces Publication of Discovery, Preclinical, and Phase 1 Clinical Trial Results of Ecnoglutide (XW003) in Molecular Metabolism
HANGZHOU, China and SAN FRANCISCO, July 12, 2023 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced the publication of discovery, preclinical characteriza...
2023-07-12 10:00
4199
GI Dynamics Announces Company Rebrand as Morphic Medical® Reintroducing Flagship Product as RESET®
BOSTON, July 11, 2023 /PRNewswire/ -- GI Dynamics, creator of the world's first medical device designed to target the underlying cause of type 2 diabetes, is proud to announce its rebrand to Morphic Medical and the introduction of RESET, formally known as EndoBarrier®. This transformative shift r...
2023-07-12 07:12
2813
Race executes global license agreement with City of Hope to access FTO IP
* Race executes worldwide license agreement with City of Hope, one of the largest cancer research and treatment organisations inthe United States. * Under the agreement, Race will exclusively secure rights to a City of Hope patent application and associated know-how identifying that bisantrene...
2023-07-11 07:30
4082
Rx-360 Expands Trademark Portfolio to Japan
PHILADELPHIA, July 10, 2023 /PRNewswire/ -- Rx-360 is pleased to announce that the consortium has now expanded their trademark registration for Joint Audit Program® logo to now include Japan. Through the achievement of this milestone, Rx-360 has secured trademark registration for Rx360 and the J...
2023-07-10 18:00
2647
Calling Bright Minds in Southeast Asia, Bio Farma and MIT Hacking Medicine is Set to Revolutionize Healthcare with a 4-Day Hackathon
JAKARTA, Indonesia, July 10, 2023 /PRNewswire/ -- Bio Farma
2023-07-10 15:19
3910
RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential of RC88 and RC108 Combined with PD-1 Therapy for Advanced Solid Tumors
The partnership focuses on combining novel antibody-drug conjugates RC88 and
RC108 with a PD-1 inhibitor sintilimab for enhanced treatment outcomes
YANTAI, China, July 10, 2023 /PRNewswire/ -- RemeGen Co., Ltd.
2023-07-10 10:24
3381
Kexing Biopharm Makes it into China's Top 20 Biopharmaceutical Enterprises (Blood Products, Vaccines and Insulin) for Two Consecutive Years
SHENZHEN, China, July 7, 2023 /PRNewswire/ -- Kexing Biopharmaceutical (688136.SH) has accomplished the impressive feat of being recognized onJune 27 as one of "China's Top 20 Biopharmaceutical Enterprises" (blood products, vaccines and insulin) for two consecutive years. This prestigious sub-lis...
2023-07-07 19:43
6244
Transcenta Received Approvals from China CDE and South Korea MFDS to Initiate TranStar 301 Global Phase III Pivotal Trial of Osemitamab (TST001)
SUZHOU, China, July 7, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has received ...
2023-07-07 15:52
4435
CARING PHARMACY CELEBRATES UNIFIED CARING MEMBERSHIP PROGRAMME WITH GEORGETOWN PHARMACY AND WELLINGS PHARMACY
KUALA LUMPUR, Malaysia, July 6, 2023 /PRNewswire/ -- CARiNG Pharmacy, Georgetown Pharmacy, and Wellings Pharmacy, all subsidiaries under CARiNG Pharmacy Group, are proud to announce their newly revamped Caring Membership Mobile App which unifies all 3 pharmacies' membership programme into one. To...
2023-07-06 18:00
4596
MGI's DNBSEQ-T7* Receives Approval for Clinical Use in South Korea
SEOUL, South Korea, July 6, 2023 /PRNewswire/ -- MGI Tech Co. Ltd. (MGI), a company committed to building core tools and technology to lead life science, announced its ultra-high-throughput genetic sequencer DNBSEQ-T7 received the medical device registration certificate from the Korea Ministry of...
2023-07-06 09:00
4166
Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure
Extension of BRII-179 license from VBI Vaccines to global rights bolsters Brii Bio's position to achieve best-in-class HBV functional cure in broad patient populations Company also acquires exclusive rights to PreHevbri®, a clinically differentiated, 3-antigen prophylactic vaccine, from VBI inGr...
2023-07-06 07:25
5007
Week's Top Stories
Most Reposted
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
[Picked up by 312 media titles]
2026-10-13 10:00
Agoda and Emerging Travel Group Enter Strategic Partnership
[Picked up by 293 media titles]
2026-10-15 16:00Food & Hospitality Asia 2027 Redefining Excellence: The Premier Platform for Food & Beverage and Hospitality Innovation
[Picked up by 282 media titles]
2026-10-15 10:00SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
[Picked up by 281 media titles]
2026-10-19 13:18
Leading Asian DMC Discova to Attend ITB Asia 2026
[Picked up by 280 media titles]
2026-10-15 12:59
Most Read
Sonilo Raises $11M to Build the AI-Native Audio Stack for Video
2026-10-15 00:00
23819
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
2026-10-13 10:00
23101
Agoda and Emerging Travel Group Enter Strategic Partnership
2026-10-15 16:00
12776